newsfilter
← Latest News
GlobeNewswire·

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

– Company reports $12.7 million in revenue in Q2'25, consisting primarily of $4.5 million in YCANTH® revenue, net, reflecting sequential growth of 32.5% over Q1'25 and $8.0 million in milestone revenue from Torii